Table 3:

Complications

Variable	Placebo (N=36)	Sitagliptin (N=44)	P-value
Composite Complications, n (%)	5 (14%)	8 (18%)	0.76
Gastrointestinal, n (%)	1 (3%)	4 (9%)	0.37
Ileus, n (%)	1 (3%)	2 (5%)	1.00
Nausea, n (%)	0 (0%)	1 (2%)	1.00
Vomiting, n (%)	0 (0%)	2 (5%)	0.50
Diarrhea, n (%)	0 (0%)	1 (2%)	1.00
Abdominal Pain, n (%)	1 (3%)	1 (2%)	1.00
AKI*, n (%)	1 (3%)	1 (2%)	1.00
Chest pain, n (%)	0 (0%)	1 (2%)	1.00
Thrombosis, n (%)	1 (3%)	0 (0%)	0.45
Pulmonary Embolism, n (%)	0 (0%)	1 (2%)	1.00
Bronchospasm, n (%)	1 3%)	0 (0%)	0.45
Re-intervention, n (%)	1 (3%)	2 (5%)	1.00
Other, No. (%)α	1 (3%)	0 (0%)	0.45
Postoperative ICU, n (%)	1 (3%)	2 (5%)	1.00
ICU length of stay, days, Median (Q1,Q3)	2.0 (2.0,2.0)	1.5 (1.0,2.0)	0.48
Total LOS, days (Median,Q1,Q3)β	3.5 (2.0,6.0)	3.0 (2.0,7.0)	0.84

^*AKI: acute kidney injury with rise in creatinine by 38 μmol/L from baseline, ICU: Intensive Care Unit, LOS: Length of Stay

^αOther: tachycardia and anemia (same patient)

^βQ1,Q3: Interquartile range 1–3